Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors

NCT05958121 is registered in ClinicalTrials.gov with Immatics Biotechnologies GmbH as lead sponsor.

NCT NCT05958121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05958121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors
Lead sponsor
Immatics Biotechnologies GmbH
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 9, 2023
Completion date
September 30, 2027
Enrollment
400 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, recurrent cancer, refractory cancer, solid tumor, adult